BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Chavannes NH, Wijsenbeek MS. Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. Am J Respir Crit Care Med 2020;202:393-401. [DOI: 10.1164/rccm.202002-0328oc] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Althobiani M, Alqahtani JS, Hurst JR, Russell AM, Porter J. Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians. BMJ Open Respir Res 2021;8:e001088. [PMID: 34969772 DOI: 10.1136/bmjresp-2021-001088] [Reference Citation Analysis]
2 O'Carroll O, MacCann R, O'Reilly A, Dunican EM, Feeney ER, Ryan S, Cotter A, Mallon PW, Keane MP, Butler MW, McCarthy C. Remote monitoring of oxygen saturation in individuals with COVID-19 pneumonia. Eur Respir J 2020;56:2001492. [PMID: 32616588 DOI: 10.1183/13993003.01492-2020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
3 Shah NM, Kaltsakas G. Telemedicine in the management of patients with chronic respiratory failure. Breathe (Sheff) 2021;17:210008. [PMID: 34295411 DOI: 10.1183/20734735.0008-2021] [Reference Citation Analysis]
4 Nakshbandi G, Moor CC, Wijsenbeek MS. Home monitoring for patients with ILD and the COVID-19 pandemic. Lancet Respir Med 2020;8:1172-4. [PMID: 33075296 DOI: 10.1016/S2213-2600(20)30452-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
5 Nakshbandi G, Moor CC, Johannson KA, Maher TM, Kreuter M, Wijsenbeek MS. Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Res 2021;7:00405-2021. [PMID: 34471631 DOI: 10.1183/23120541.00405-2021] [Reference Citation Analysis]
6 Podolanczuk AJ, Richeldi L. COVID-19 and Interstitial Lung Disease: Keep Them Separate. Am J Respir Crit Care Med 2020;202:1614-6. [PMID: 33113338 DOI: 10.1164/rccm.202010-3918ED] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wijsenbeek M, Molina-Molina M, Chassany O, Fox J, Galvin L, Geissler K, Hammitt KM, Kreuter M, Moua T, O'Brien EC, Slagle AF, Krasnow A, Reaney M, Baldwin M, Male N, Rohr KB, Swigris J, Antoniou K. Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures. ERJ Open Res 2022;8:00681-2021. [PMID: 35509443 DOI: 10.1183/23120541.00681-2021] [Reference Citation Analysis]
8 Althobiani MA, Evans RA, Alqahtani JS, Aldhahir AM, Russell AM, Hurst JR, Porter JC. Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. ERJ Open Res 2021;7:00441-2021. [PMID: 34938799 DOI: 10.1183/23120541.00441-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nakshbandi G, Moor CC, Nossent EJ, Geelhoed JJM, Baart SJ, Boerrigter BG, Aerts JGJV, Nijman SFM, Santema HY, Hellemons ME, Wijsenbeek MS. Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection: The HOMECOMIN' study. Respirology 2022. [PMID: 35441433 DOI: 10.1111/resp.14262] [Reference Citation Analysis]
10 Dobler CC. Models of healthcare in respiratory diseases. Breathe (Sheff) 2020;16:200213. [PMID: 33447280 DOI: 10.1183/20734735.0213-2020] [Reference Citation Analysis]
11 Chiner-vives E, Cordovilla-pérez R, Rosa-carrillo DDL, García-clemente M, Izquierdo-alonso JL, Otero-candelera R, Llano LP, Sellares-torres J, Granda-orive JID. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Archivos de Bronconeumología 2022. [DOI: 10.1016/j.arbres.2022.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Noth I, Cottin V, Chaudhuri N, Corte TJ, Johannson KA, Wijsenbeek M, Jouneau S, Michael A, Quaresma M, Rohr KB, Russell AM, Stowasser S, Maher TM; INMARK trial investigators. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. Eur Respir J 2021;58:2001518. [PMID: 33419890 DOI: 10.1183/13993003.01518-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Veit T, Barnikel M, Crispin A, Kneidinger N, Ceelen F, Arnold P, Munker D, Schmitzer M, Barton J, Schiopu S, Schiller HB, Frankenberger M, Milger K, Behr J, Neurohr C, Leuschner G. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respir Res 2020;21:270. [PMID: 33076914 DOI: 10.1186/s12931-020-01524-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Jain S, Santhosh L. On Treatments and Tests Deferred: Preparing for Collateral Damage from COVID-19. Ann Am Thorac Soc 2020;17:1371-3. [PMID: 32667208 DOI: 10.1513/AnnalsATS.202004-387VP] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Qin H, Tang Y, Mao Y, Zhou X, Xu T, Liu W, Su X. C-MYC induces idiopathic pulmonary fibrosis via modulation of miR-9-5p-mediated TBPL1. Cell Signal 2022;:110274. [PMID: 35122989 DOI: 10.1016/j.cellsig.2022.110274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, Kimman ML, Wijsenbeek MS. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respir Res 2020;21:196. [PMID: 32703201 DOI: 10.1186/s12931-020-01458-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
17 Moor CC, van Leuven SI, Wijsenbeek MS, Vonk MC. Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. Rheumatology (Oxford) 2021;60:2467-71. [PMID: 33212511 DOI: 10.1093/rheumatology/keaa607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
18 Saketkoo LA, Russell AM, Jensen K, Mandizha J, Tavee J, Newton J, Rivera F, Howie M, Reese R, Goodman M, Hart P, Strookappe B, De Vries J, Rosenbach M, Scholand MB, Lammi MR, Elfferich M, Lower E, Baughman RP, Sweiss N, Judson MA, Drent M. Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics (Basel) 2021;11:1089. [PMID: 34203584 DOI: 10.3390/diagnostics11061089] [Reference Citation Analysis]
19 Wijsenbeek MS, Bendstrup E, Valenzuela C, Henry MT, Moor CC, Jouneau S, Fois AG, Moran-Mendoza O, Anees S, Mirt M, Bengus M, Gilberg F, Kirchgaessler KU, Vancheri C. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Adv Ther 2021;38:4040-56. [PMID: 34117601 DOI: 10.1007/s12325-021-01790-y] [Reference Citation Analysis]
20 Wijbenga N, Hoek RAS, Mathot BJ, Seghers L, van Weezel JJ, den Ouden J, Wijsenbeek MS, Aerts JGJV, Hellemons ME, Moor CC. Evaluation of a Home Monitoring Application for Follow Up after Lung Transplantation-A Pilot Study. J Pers Med 2020;10:E240. [PMID: 33233334 DOI: 10.3390/jpm10040240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Coskun F, Hanta I, Cilli A, Ozkaya G, Ursavas A, Sevinc C. Effects of the COVID-19 pandemic on the follow-up and treatment of patients with idiopathic pulmonary fibrosis: a cross-sectional, multicentre phone call survey. BMJ Open 2021;11:e050578. [PMID: 34385255 DOI: 10.1136/bmjopen-2021-050578] [Reference Citation Analysis]
22 Johannson KA. Remote Monitoring in Idiopathic Pulmonary Fibrosis: Home Is Where the Bluetooth-enabled Spirometer Is. Am J Respir Crit Care Med 2020;202:316-7. [PMID: 32402209 DOI: 10.1164/rccm.202005-1532ED] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
23 Miedema JR, Moor CC, Veltkamp M, Baart S, Lie NSL, Grutters JC, Wijsenbeek MS, Mostard RLM. Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study. Respir Res 2022;23. [DOI: 10.1186/s12931-022-02061-2] [Reference Citation Analysis]